Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

Efficacy of a CD22-targeted antibody-saporin conjugate in a xenograft model of precursor-B cell acute lymphoblastic leukemia.

Kato J, Satake N, O'Donnell RT, Abuhay M, Lewis C, Tuscano JM.

Leuk Res. 2013 Jan;37(1):83-8. doi: 10.1016/j.leukres.2012.09.010. Epub 2012 Oct 4.

PMID:
23040543
2.
3.

Targeting CD22 in B-cell malignancies: current status and clinical outlook.

Sullivan-Chang L, O'Donnell RT, Tuscano JM.

BioDrugs. 2013 Aug;27(4):293-304. doi: 10.1007/s40259-013-0016-7. Review.

PMID:
23696252
4.

Preclinical studies with the anti-CD19-saporin immunotoxin BU12-SAPORIN for the treatment of human-B-cell tumours.

Flavell DJ, Flavell SU, Boehm DA, Emery L, Noss A, Ling NR, Richardson PR, Hardie D, Wright DH.

Br J Cancer. 1995 Dec;72(6):1373-9.

5.

Treatment of SCID/human B cell precursor ALL with anti-CD19 and anti-CD22 immunotoxins.

Herrera L, Yarbrough S, Ghetie V, Aquino DB, Vitetta ES.

Leukemia. 2003 Feb;17(2):334-8.

PMID:
12592332
6.

An anti-CD72 immunotoxin against therapy-refractory B-lineage acute lymphoblastic leukemia.

Myers DE, Uckun FM.

Leuk Lymphoma. 1995 Jun;18(1-2):119-22.

PMID:
8580813
7.

Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia.

Dijoseph JF, Dougher MM, Armellino DC, Evans DY, Damle NK.

Leukemia. 2007 Nov;21(11):2240-5. Epub 2007 Jul 26.

PMID:
17657218
8.
9.

Efficacy and toxicity of a CD22-targeted antibody-saporin conjugate in a xenograft model of non-Hodgkin's lymphoma.

Kato J, O'Donnell RT, Abuhay M, Tuscano JM.

Oncoimmunology. 2012 Dec 1;1(9):1469-1475.

10.

In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against human pre-B cell acute lymphoblastic leukemia in mice with severe combined immunodeficiency.

Uckun FM, Manivel C, Arthur D, Chelstrom LM, Finnegan D, Tuel-Ahlgren L, Irvin JD, Myers DE, Gunther R.

Blood. 1992 May 1;79(9):2201-14.

11.
12.

Dose, timing, schedule, and the choice of targeted epitope alter the efficacy of anti-CD22 immunotherapy in mice bearing human lymphoma xenografts.

O'Donnell RT, Ma Y, McKnight HC, Pearson D, Tuscano JM.

Cancer Immunol Immunother. 2009 Dec;58(12):2051-8. doi: 10.1007/s00262-009-0713-8. Epub 2009 May 13.

13.
14.

Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia.

Haso W, Lee DW, Shah NN, Stetler-Stevenson M, Yuan CM, Pastan IH, Dimitrov DS, Morgan RA, FitzGerald DJ, Barrett DM, Wayne AS, Mackall CL, Orentas RJ.

Blood. 2013 Feb 14;121(7):1165-74. doi: 10.1182/blood-2012-06-438002. Epub 2012 Dec 14.

17.

Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts.

Tuscano JM, O'Donnell RT, Miers LA, Kroger LA, Kukis DL, Lamborn KR, Tedder TF, DeNardo GL.

Blood. 2003 May 1;101(9):3641-7. Epub 2003 Jan 2.

18.

Anti-CD22-MCC-DM1: an antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin's lymphoma.

Polson AG, Williams M, Gray AM, Fuji RN, Poon KA, McBride J, Raab H, Januario T, Go M, Lau J, Yu SF, Du C, Fuh F, Tan C, Wu Y, Liang WC, Prabhu S, Stephan JP, Hongo JA, Dere RC, Deng R, Cullen M, de Tute R, Bennett F, Rawstron A, Jack A, Ebens A.

Leukemia. 2010 Sep;24(9):1566-73. doi: 10.1038/leu.2010.141. Epub 2010 Jul 1.

PMID:
20596033
20.

Effects of specific anti-B and/or anti-plasma cell immunotherapy on antibody production in baboons: depletion of CD20- and CD22-positive B cells does not result in significantly decreased production of anti-alphaGal antibody.

Alwayn IP, Xu Y, Basker M, Wu C, Buhler L, Lambrigts D, Treter S, Harper D, Kitamura H, Vitetta ES, Abraham S, Awwad M, White-Scharf ME, Sachs DH, Thall A, Cooper DK.

Xenotransplantation. 2001 Aug;8(3):157-71.

PMID:
11472623

Supplemental Content

Support Center